Logan Capital Management Inc. Decreases Holdings in AbbVie Inc. $ABBV

Logan Capital Management Inc. lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 79,419 shares of the company’s stock after selling 8,592 shares during the quarter. AbbVie makes up about 0.8% of Logan Capital Management Inc.’s portfolio, making the stock its 28th largest position. Logan Capital Management Inc.’s holdings in AbbVie were worth $18,146,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Woodley Farra Manion Portfolio Management Inc. increased its holdings in AbbVie by 57.3% during the fourth quarter. Woodley Farra Manion Portfolio Management Inc. now owns 23,199 shares of the company’s stock worth $5,301,000 after buying an additional 8,453 shares during the last quarter. Cowa LLC increased its holdings in AbbVie by 19.8% during the fourth quarter. Cowa LLC now owns 6,165 shares of the company’s stock worth $1,409,000 after buying an additional 1,018 shares during the last quarter. Absolute Capital Management LLC increased its holdings in AbbVie by 18.5% during the fourth quarter. Absolute Capital Management LLC now owns 1,158 shares of the company’s stock worth $265,000 after buying an additional 181 shares during the last quarter. Nuveen LLC increased its holdings in AbbVie by 6.5% during the fourth quarter. Nuveen LLC now owns 8,608,026 shares of the company’s stock worth $1,966,848,000 after buying an additional 524,495 shares during the last quarter. Finally, Xponance LLC increased its stake in shares of AbbVie by 3.4% in the fourth quarter. Xponance LLC now owns 479,552 shares of the company’s stock worth $109,573,000 after purchasing an additional 15,898 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABBV shares. Evercore set a $235.00 target price on shares of AbbVie in a research note on Friday, May 15th. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Monday. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Finally, Guggenheim reiterated a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Trading Up 0.0%

Shares of NYSE:ABBV opened at $225.04 on Friday. The company has a 50 day moving average of $210.80 and a 200 day moving average of $219.01. The stock has a market cap of $397.60 billion, a P/E ratio of 110.86, a P/E/G ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 12 month low of $181.73 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.